A
ABCL
Abcellera Biologics Inc.
12.61
-0.03-0.20%After Hours: 12.60 -0.01 -0.08%19:57 10/13 EDT
OPEN/PREV CLOSE12.53/12.64
TODAY RANGE12.20-12.72
VOL3.25M
MARKET CAP4.08B
52 WEEK RANGE2.745-15.02
AVG VOL (3M)6.68M
% TURNOVER0.94%
TURNOVER--
P/E (TTM)-23.1504
% RANGE4.12%
EPS(TTM)-0.5447
P/E(FORWARD)-18.8818
P/B4.313
BVPS2.924
DIVIDEND--
P/S50.46
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP3.20B
SHARES OUTSTANDING323.91M
NEXT EARNINGS11/04-11/09
FREE FLOAT253.50M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·20h ago
After AbCellera Biologics' 125% Climb, The Story Has Changed
TipRanks·2d ago
AbCellera initiated with a Buy at UBS
Simply Wall St·3d ago
Is AbCellera Biologics (ABCL) Undervalued After New ABCL635 Data Presentation Plans?
Simply Wall St·4d ago
Clinical Data Update Might Change The Case For Investing In AbCellera Biologics Stock
NASDAQ·09/30 10:14
Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT
TipRanks·09/29 19:05
AbCellera Biologics call volume above normal and directionally bullish
Dow Jones·09/29 13:25
AbCellera Biologics Initiated at Overweight by JP Morgan
Dow Jones·09/29 13:25
AbCellera Biologics Price Target Announced at $17.00/Share by JP Morgan
TipRanks·09/29 10:05
AbCellera initiated with an Overweight at JPMorgan
TipRanks·09/27 21:55
JonesTrading Sticks to Their Buy Rating for AbCellera Biologics (ABCL)
Simply Wall St·09/26 21:18
Is AbCellera Biologics (ABCL) Undervalued On Its ABCL635 Phase 2 Data Presentation?
Simply Wall St·09/24 22:30
How Investors Are Reacting To AbCellera Stock As Phase 2 Data Nears
Seeking Alpha·09/24 18:59
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
Same Industry
Name/Symbol
Change%
Price